Use of margarine enriched in phytosterols by patients at high cardiovascular risk and treated by hypolipidemic drugs
| Autor: | Philippe Moulin, Marie-Sophie Schwalm, Laurent Laforest, Eric Van Ganse, Philippe Le Jeunne, J. Massol, Brice Kitio, S. Chretin |
|---|---|
| Přispěvatelé: | Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Régulations métaboliques, nutrition et diabètes (RMND), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), UFR de Médecine, Université de Franche-Comté (UFC), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC) |
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Male
medicine.medical_specialty Endocrinology Diabetes and Metabolism Population Cardiovascular risk factors Medicine (miscellaneous) Disease 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Age Distribution Risk Factors Internal medicine Odds Ratio Confidence Intervals Medicine Humans In patient 030212 general & internal medicine Sex Distribution education Aged Retrospective Studies Hypolipidemic Agents Secondary prevention education.field_of_study Nutrition and Dietetics business.industry Prevention Phytosterol-enriched margarines Phytosterols Middle Aged Fortified medicine.disease Margarine 3. Good health Dyslipidemia Cardiovascular Diseases Food Baseline characteristics Food Fortified Female [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie Cardiology and Cardiovascular Medicine business Hypolipidemic Drugs |
| Zdroj: | Nutrition, metabolism, and cardiovascular diseases: NMCD Nutrition, metabolism, and cardiovascular diseases: NMCD, 2007, 17 (9), pp.657--665. ⟨10.1016/j.numecd.2006.07.012⟩ |
| Popis: | International audience; BACKGROUND AND AIMS: The use of phytosterol-enriched margarines (PEM) in patients at cardiovascular risk has not been thoroughly explored. We determined the proportion of users of PEM in a population at high cardiovascular risk, and their characteristics. In addition, the correlates of using at least 25 g/d of PEM were identified. METHODS AND RESULTS: Patients with at least two cardiovascular risk factors in addition to dyslipidemia (primary prevention) or with past cardiovascular disease (secondary prevention) were recruited by general practitioners (GPs). Baseline characteristics were collected from a computerized GP database linked to a survey. GPs recorded patterns of PEM use. First, users were compared with non-users. Then, analyses were conducted to identify characteristics of patients using PEM at a recommended dose (\\textgreateror=25 g/d). Among 1631 patients with documented consumption, a minority used PEM (15.2%), and only 36.4% of consumers used it at recommended level. Overall, PEM users did not differ from non-users as to general characteristics, nor as to the level of cardiovascular risk in primary prevention. However, PEM users reported significantly more cardiovascular events among their parents (OR=1.4; 95% CI=[1.0-1.9]). Consumers who used at least 25 g/d of PEM were more likely to be men (OR=3.1; 95% CI=[1.6-5.8]), to be aged 60-74 (OR=3.0; 95% CI=[1.4-6.4]), or 75 or older (OR=4.0; 95% CI=[1.5-10.6]). Again, no difference was observed regarding the level of cardiovascular risk. CONCLUSIONS: The level of use of PEM was low in this population of high cardiovascular risk patients. In addition, only a third of users consumed margarine at the recommended level. Our data suggest that pattern of use of PEM is not related to the level of cardiovascular risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|